Trial Profile
Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jan 2018
Price :
$35
*
At a glance
- Drugs Finafloxacin (Primary)
- Indications Bacterial infections; Helicobacter infections; Otitis externa; Otitis media; Pyelonephritis; Respiratory tract infections; Urinary tract infections
- Focus Adverse reactions
- Sponsors MerLion Pharmaceuticals
- 16 Jan 2018 Results (n=266) of pooled data from three trial assessing population pharmacokinetics of finafloxacin in healthy volunteers and patients with complicated urinary tract infections, were published in the Antimicrobial Agents and Chemotherapy.
- 07 Aug 2017 Results published in the Antimicrobial Agents and Chemotherapy
- 05 Aug 2013 New trial record